Restricted accessCase reportFirst published online 2014-3
Extraordinary Giant Basal Cell Carcinoma with Full-Thickness Infiltration of the Abdominal Wall: Single-Staged Resection and Simultaneous Reconstruction
Basal cell carcinoma (BCC) is the most frequent form of invasive skin cancer. BCCs usually show a slow progression and rarely metastasize; however, around 1% achieve a “giant” size, larger than 5 cm in diameter. Rarely, BCCs larger than 20 cm are reported in the literature.
Objective:
We report a case of a giant BCC, measuring 25 × 13 × 5 cm, involving the abdominal wall. The article describes the curative surgical procedure, which resulted in an excellent aesthetic result.
Get full access to this article
View all access options for this article.
References
1.
RandleHW. Basal cell carcinoma. Identification and treatment of the high-risk patient. Dermatol Surg1996;22:255–61.
2.
TaylorGICorlettRBoydJB. The extended deep inferior epigastric flap: a clinical technique. Plast Reconstr Surg1983;72: 751–65, doi:10.1097/00006534-198312000-00001.
3.
NevilleJAWelchELeffellDJ. Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol2007;4:462–9, doi:10.1038/ncponc0883.
4.
LorenziniMGattiSGiannitrapaniA. Giant basal cell carcinoma of the thoracic wall: a case report and review of the literature. Br J Plast Surg2005;58:1007–10, doi:10.1016/j.bjps.2005.04.017.
5.
RandleHWRoenigkRKBrodlandDG. Giant basal cell carcinoma (T3). Who is at risk? Cancer1993;1;72:1624–30, doi:10.1002/1097-0142(19930901)72:5<1624::AID-CNCR2820720 522>3.0.CO;2-D.
6.
de BreeELaliotisAManiosA. Super giant basal cell carcinoma of the abdominal wall: still possible in the 21st century. Int J Dermatol2010;49:806–9.
7.
KikuchiMYanoKKuboT. Giant basal cell carcinoma affecting the lower abdominal, genital and bilateral inguinal regions. Br J Plast Surg2002;55:445–8, doi:10.1054/bjps.2002.3869.
8.
ArnaizJGallardoEPiedraT. Giant basal cell carcinoma on the lower leg: MRI findings. J Plast Reconstr Aesthet Surg2007;60: 1167–8, doi:10.1016/j.bjps.2007.05.014.
9.
SaranA. Basal cell carcinoma and the carcinogenic role of aberrant hedgehog signaling. Future Oncol2010;6:1003–14, doi:10.2217/fon.10.49.
10.
Von HoffDDLoRussoPMRudinCM. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med2009;361:1164–72, doi:10.1056/NEJMoa0905360.
11.
DlugoszAATalpazM. Following the hedgehog to new cancer therapies. N Engl J Med2009;361:1202–5, doi:10.1056/NEJMe0906092.
12.
GuptaSTakebeNLorussoP. Targeting the hedgehog pathway in cancer. Ther Adv Med Oncol2010;2:237–50, doi:10.1177/1758834010366430.
13.
LoRussoPMRudinCMReddyJC. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res2011;17:2502–11, doi:10.1158/1078-0432.CCR-10-2745.
